Health-Related Quality of Life Outcomes in PARADIGM-HF [Original Articles]

Conclusions Change scores in KCCQ clinical summary scores and KCCQ overall summary scores were better in patients treated with sacubitril/valsartan compared with those treated with enalapril, with consistency in most domains, and persist during follow-up beyond 8 months. These findings demonstrate that sacubitril/valsartan leads to better HRQL in surviving patients with heart failure. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT01035255.

http://circheartfailure.ahajournals.org/cgi/content/short/10/8/e003430?rss=1

Source: Circulation: Heart Failure - August 7, 2017 Category: Cardiology Authors: Lewis, E. F., Claggett, B. L., McMurray, J. J. V., Packer, M., Lefkowitz, M. P., Rouleau, J. L., Liu, J., Shi, V. C., Zile, M. R., Desai, A. S., Solomon, S. D., Swedberg, K. Tags: Heart Failure Original Articles Source Type: research